Clinical Trial Results:
A phase I, randomized, controlled, double-blind study to assess safety, reactogenicity and immunogenicity of GSK Biologicals’ pneumococcal vaccine 2830930A when administered as a single dose in healthy toddlers aged 12-23 months.
Summary
|
|
EudraCT number |
2011-002225-22 |
Trial protocol |
DE |
Global end of trial date |
15 Mar 2012
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
27 Feb 2019
|
First version publication date |
24 May 2015
|
Other versions |
v1 |
Version creation reason |
|
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
115373
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01485406 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
GlaxoSmithKline Biologicals
|
||
Sponsor organisation address |
Rue de l'Institut 89, Rixensart, Belgium,
|
||
Public contact |
Clinical Disclosure Advisor, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
|
||
Scientific contact |
Clinical Disclosure Advisor, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
26 Nov 2018
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
15 Mar 2012
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
15 Mar 2012
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
• To assess safety and reactogenicity of 1 dose of 2830930A vaccine administered to toddlers aged 12-23 months primed with 3 doses of Synflorix™, in terms of occurrence of grade 3 related solicited and unsolicited adverse events and related serious adverse events.
|
||
Protection of trial subjects |
All subjects were supervised after vaccination with appropriate medical treatment readily available. Vaccines were administered by qualified and trained personnel. Only eligible subjects that had no contraindications to any components of the vaccines were vaccinated. Subjects were followed-up for 31 days after each/last vaccination
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
07 Dec 2011
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 61
|
||
Worldwide total number of subjects |
61
|
||
EEA total number of subjects |
61
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
61
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
Among the 61 enrolled and vaccinated subjects, 60 subjects completed the study. | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms. | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Overall trial (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind | |||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Carer, Assessor | |||||||||||||||
Blinding implementation details |
In a double blind study, the subject, the investigator and sponsor staff who are involved in the treatment or clinical evaluation of the subjects and the review or analysis of data were all unaware of the treatment assignment. The serological data, which would lead to the unblinding of the treatment groups, were not available during the course of the study to any investigator or any person involved in the clinical conduct of the study (including data cleaning).
|
|||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
12Pn-PD-DiT-CRM group | |||||||||||||||
Arm description |
This group included toddlers aged 12-23 months primed with 3 doses of Synflorix outside the study, who received a single dose of GSK 12-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate (GSK2830930A) vaccine at Study Month 0. Study duration was of about 1 month. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
GSK2189242A
|
|||||||||||||||
Investigational medicinal product code |
GSK2189242A
|
|||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Suspension for injection in pre-filled syringe
|
|||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||
Dosage and administration details |
one dose administered intramuscularly in the deltoid of the non-dominant arm.
|
|||||||||||||||
Arm title
|
Synflorix group | |||||||||||||||
Arm description |
This group included toddlers aged 12-23 months primed with 3 doses of Synflorix outside the study, who received a single dose Synflorix at Study Month 0. Study duration was of about 1 month. | |||||||||||||||
Arm type |
Active comparator | |||||||||||||||
Investigational medicinal product name |
Synflorix
|
|||||||||||||||
Investigational medicinal product code |
GSK1024850A
|
|||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection in pre-filled syringe
|
|||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||
Dosage and administration details |
one dose administered intramuscularly in the deltoid of the non-dominant arm.
|
|||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
12Pn-PD-DiT-CRM group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
This group included toddlers aged 12-23 months primed with 3 doses of Synflorix outside the study, who received a single dose of GSK 12-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate (GSK2830930A) vaccine at Study Month 0. Study duration was of about 1 month. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Synflorix group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
This group included toddlers aged 12-23 months primed with 3 doses of Synflorix outside the study, who received a single dose Synflorix at Study Month 0. Study duration was of about 1 month. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
12Pn-PD-DiT-CRM group
|
||
Reporting group description |
This group included toddlers aged 12-23 months primed with 3 doses of Synflorix outside the study, who received a single dose of GSK 12-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate (GSK2830930A) vaccine at Study Month 0. Study duration was of about 1 month. | ||
Reporting group title |
Synflorix group
|
||
Reporting group description |
This group included toddlers aged 12-23 months primed with 3 doses of Synflorix outside the study, who received a single dose Synflorix at Study Month 0. Study duration was of about 1 month. |
|
|||||||||||||||||||
End point title |
Number of subjects with grade 3 solicited local symptoms [1] | ||||||||||||||||||
End point description |
Local symptoms were pain, redness and swelling at injection site. Grade 3 Pain = Crying when limb was moved/spontaneously painful. Grade 3 Redness/Swelling = Redness/swelling at injection site larger than (>) 30 millimeters (mm). All solicited local AEs were considered as causally related to the study vaccination.
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
during the 7-day (Days 0-6) post-vaccination period
|
||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This endpoint contains only descriptive results. No inferential results. |
|||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||
End point title |
Number of subjects with grade 3 solicited general symptoms with relationship to vaccination [2] | |||||||||||||||||||||||||||||||||
End point description |
Solicited general symptoms were Drowsiness, Irritability, Loss of appetite and Fever (rectal temperature higher than or equal to [>=] 38 degrees Celsius [°C]). Grade 3 Drowsiness = Drowsiness that prevented normal activity. Grade 3 Irritability = Crying that could not be comforted/prevented normal activity. Grade 3 Loss of appetite = Subject did not eat at all. Grade 3 Fever = Rectal temperature higher than (>) 40.0°C. Grade 3 & related (Gr.3 & related) = grade 3 symptoms assessed by the investigators as causally related to vaccination.
|
|||||||||||||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||||||||||||||
End point timeframe |
during the 7-day (Days 0-6) post-vaccination period
|
|||||||||||||||||||||||||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This endpoint contains only descriptive results. No inferential results. |
||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||
End point title |
Number of subjects with grade 3 unsolicited adverse events (AEs) with relationship to vaccination [3] | |||||||||||||||
End point description |
An unsolicited AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse. Grade 3 AE = Occurrence of AE which prevented normal activities. Grade 3 and Related AE= Grade 3 AE assessed by the investigator as causally related to vaccination.
|
|||||||||||||||
End point type |
Primary
|
|||||||||||||||
End point timeframe |
within 31 days (Day 0-Day 30) after vaccination
|
|||||||||||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This endpoint contains only descriptive results. No inferential results. |
||||||||||||||||
|
||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of subjects with serious adverse events (SAEs) with relationship to vaccination [4] | ||||||||||||
End point description |
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity. These should also be considered serious: invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation. Related SAE= SAE assessed by the investigator as causally related to vaccination.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
throughout the entire study (from Month 0 up to Month 1)
|
||||||||||||
Notes [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This endpoint contains only descriptive results. No inferential results. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Antibody concentrations against vaccine serotypes 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | ||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Antibody concentrations were measured by 22F-inhibition Enzyme-Linked ImmunoSorbent Assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The cut-off of the assay was an antibody concentration higher than or equal to (≥) 0.05 µg/mL.
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
1 month post-vaccination
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||
End point title |
Antibody concentrations against Protein D (PD) | |||||||||||||||
End point description |
Anti-PD antibody concentrations were measured by Enzyme-Linked ImmunoSorbent Assay (ELISA), expressed as geometric mean concentrations (GMCs), in Elisa Units per milliliter (EL.U/mL). The cut-off of the assay was an anti-PD antibody concentration higher than or equal to (≥) 100 EL.U/mL.
|
|||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
1 month post-vaccination
|
|||||||||||||||
|
||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Titers for opsonophagocytic activity against 6A and 19A pneumococcal serotypes | ||||||||||||||||||
End point description |
Titers for opsonophagocytic activity assessed for this outcome measure were those for opsonophagocytic activity against the pneumococcal serotypes 6A and 19A (OPA-6A and OPA-19A). The Seropositivity cut-off of the assay was a titer for opsonophagocytic activity higher than or equal to the serotype-specific Lower Limit of Quantification (LLOQ) (for OPA-6A, LLOQ =151 and for OPA-19A, LLOQ =143 ).
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
1 month post-vaccination
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Number of subjects with any solicited local symptoms | ||||||||||||||||||
End point description |
Assessed local symptoms were pain, redness and swelling at injection site. Any = Occurrence of the specified solicited local symptom, regardless of intensity.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
during the 7-day (Days 0-6) post-vaccination period
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||
End point title |
Number of subjects with any and related solicited general symptoms | |||||||||||||||||||||||||||||||||
End point description |
Solicited general symptoms were Drowsiness, Irritability, Loss of appetite (Loss Appet.) and Fever (rectal temperature higher than or equal to [>=] 38 degrees Celsius [°C]). Any = Occurrence of the specified solicited general symptom, regardless of intensity and relationship to vaccination. Related = Occurrence of the specified symptom assessed by the investigators as causally related to vaccination.
|
|||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||
End point timeframe |
during the 7-day (Days 0-6) post-vaccination period
|
|||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||
End point title |
Number of subjects with any and related unsolicited adverse events (AEs) | |||||||||||||||
End point description |
An unsolicited AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a
medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse. Any = Occurrence of AE, regardless of intensity or relationship to vaccination. Related AE = AE assessed by the investigator as causally related to vaccination.
|
|||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
within 31 days (Day 0-Day 30) after vaccination
|
|||||||||||||||
|
||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of subjects with any serious adverse events (SAEs) | ||||||||||||
End point description |
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity. These should also be considered serious: invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation. Any = Occurrence of an SAE, regardless of relationship to vaccination.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
throughout the entire study (from Month 0 to Month 1)
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Solicited symptoms: during the 7 days after vaccination. Unsolicited AEs during 31 days after vaccination. SAEs: during the entire study period (Months 0-1).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Solicited symptoms results are presented only for subjects for whom results were available.
Note: the occurences (all) numbers were not calculated during the analysis: data entered are equal to the subject affected numbers.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
15.0
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
12Pn-PD-DiT-CRM group
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
This group consisted in toddlers aged 12-23 months primed with 3 doses of Synflorix™ who received a single dose of GSK 12-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate (GSK2830930A) vaccine at Study Month 0. Study duration was of about 1 month. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Synflorix™ group
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
This group consisted in toddlers aged 12-23 months primed with 3 doses of Synflorix™ who received a single dose Synflorix™ at Study Month 0. Study duration was of about 1 month. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: Solicited symptoms results are presented only for subjects for whom results were available. [2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: Solicited symptoms results are presented only for subjects for whom results were available. [3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: Solicited symptoms results are presented only for subjects for whom results were available. [4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: Solicited symptoms results are presented only for subjects for whom results were available. [5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: Solicited symptoms results are presented only for subjects for whom results were available. [6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: Solicited symptoms results are presented only for subjects for whom results were available. [7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: Solicited symptoms results are presented only for subjects for whom results were available. |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |